Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer
NCT05188781
·
clinicaltrials.gov ↗
COMPLETED
Status
34
Enrollment
OTHER
Sponsor class
Conditions
High-Grade Serous Ovarian Cancer
Interventions
DRUG:
Pembrolizumab combined Anlotinib
Sponsor
The Affiliated Hospital of Qingdao University